{"title":"储存在透明质酸修饰脂质体溶液中的纳米气泡臭氧:灭活耐药细菌和遗传毒性,亚急性和亚慢性毒性试验。","authors":"Perihan Erkan Alkan, Talha Karabiyik","doi":"10.2147/IDR.S478643","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Nanobubble ozone stored in hyaluronic acid-decorated liposomes (patent application PCT/TR2022/050177) was used, and the Minimum Inhibitory Concentration (MIC) was found to be 1562 ppm. <i>Pseudomonas aeruginosa</i> (patient isolate), <i>Acinetobacter baumannii</i> (patient isolate), <i>Methicillin-Resistant Staphylococcus aureus</i> (MRSA) (ATCC12493), and <i>Escherichia coli</i> (ATCC25922) bacteria, which are hospital-acquired and healthcare-associated infections, were used. A time-dependent efficacy study was conducted at 1600 ppm. Our study aimed to determine whether the newly developed solution maintains long-term effectiveness and can be used as an antibacterial agent, especially in intensive care units.</p><p><strong>Methods: </strong>Antibacterial tests of the nanobubble liposome solution, developed with a different technique than the standard ozonation procedures, were performed with the CLSI M07 A9 (Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard) standard test method, and the solution was tested at Minimal Inhibitory Concentration (MIC) value and time-dependent effects were determined. For the stability test of the nanobubble liposome solution, according to the ASTM F 1980 standard, it was kept at 55 °C for 74 days as two-year stability.</p><p><strong>Results: </strong>The MIC of the nanobubble ozone solution was 1.562 ppm for <i>MRSA</i> and <i>E. coli</i> (ATCC 25922) standard test method using CLSI M07 A9 (Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard). <i>P. aeruginosa, A. baumannii, Methicillin-Resistant Staphylococcus aureus</i> (MRSA) (ATCC12493), and <i>E. coli</i> (ATCC 25922). No activity was observed at 2 min, but 1600 ppm nanobubble liposomes at 10 min were found to be effective. In terms of effectiveness, the solution would still be effective after 2 years according to the ASTM F 1980 standard, contrary to expectations.</p><p><strong>Conclusion: </strong>It is thought that nanobubble ozone stored in hyaluronic acid-decorated liposome solutions will play an important role in the fight against infections because of its non-toxic effect, effectiveness against resistant bacteria, and stability for at least two years. In the following process, it would be appropriate to support the product through clinical studies.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"313-328"},"PeriodicalIF":2.9000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11745042/pdf/","citationCount":"0","resultStr":"{\"title\":\"Nanobubble Ozone Stored in Hyaluronic Acid-Decorated Liposome Solutions: Inactivating Antibiotic-Resistant Bacteria and Genotoxicity, Sub-Acute and Sub-Chronic Toxicity Tests.\",\"authors\":\"Perihan Erkan Alkan, Talha Karabiyik\",\"doi\":\"10.2147/IDR.S478643\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Nanobubble ozone stored in hyaluronic acid-decorated liposomes (patent application PCT/TR2022/050177) was used, and the Minimum Inhibitory Concentration (MIC) was found to be 1562 ppm. <i>Pseudomonas aeruginosa</i> (patient isolate), <i>Acinetobacter baumannii</i> (patient isolate), <i>Methicillin-Resistant Staphylococcus aureus</i> (MRSA) (ATCC12493), and <i>Escherichia coli</i> (ATCC25922) bacteria, which are hospital-acquired and healthcare-associated infections, were used. A time-dependent efficacy study was conducted at 1600 ppm. Our study aimed to determine whether the newly developed solution maintains long-term effectiveness and can be used as an antibacterial agent, especially in intensive care units.</p><p><strong>Methods: </strong>Antibacterial tests of the nanobubble liposome solution, developed with a different technique than the standard ozonation procedures, were performed with the CLSI M07 A9 (Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard) standard test method, and the solution was tested at Minimal Inhibitory Concentration (MIC) value and time-dependent effects were determined. For the stability test of the nanobubble liposome solution, according to the ASTM F 1980 standard, it was kept at 55 °C for 74 days as two-year stability.</p><p><strong>Results: </strong>The MIC of the nanobubble ozone solution was 1.562 ppm for <i>MRSA</i> and <i>E. coli</i> (ATCC 25922) standard test method using CLSI M07 A9 (Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard). <i>P. aeruginosa, A. baumannii, Methicillin-Resistant Staphylococcus aureus</i> (MRSA) (ATCC12493), and <i>E. coli</i> (ATCC 25922). No activity was observed at 2 min, but 1600 ppm nanobubble liposomes at 10 min were found to be effective. In terms of effectiveness, the solution would still be effective after 2 years according to the ASTM F 1980 standard, contrary to expectations.</p><p><strong>Conclusion: </strong>It is thought that nanobubble ozone stored in hyaluronic acid-decorated liposome solutions will play an important role in the fight against infections because of its non-toxic effect, effectiveness against resistant bacteria, and stability for at least two years. In the following process, it would be appropriate to support the product through clinical studies.</p>\",\"PeriodicalId\":13577,\"journal\":{\"name\":\"Infection and Drug Resistance\",\"volume\":\"18 \",\"pages\":\"313-328\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-01-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11745042/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infection and Drug Resistance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/IDR.S478643\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Drug Resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IDR.S478643","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
简介:采用透明质酸修饰脂质体(专利申请PCT/TR2022/050177)储存纳米气泡臭氧,最小抑制浓度(MIC)为1562 ppm。铜绿假单胞菌(患者分离物)、鲍曼不动杆菌(患者分离物)、耐甲氧西林金黄色葡萄球菌(MRSA) (ATCC12493)和大肠杆菌(ATCC25922)细菌均为医院获得性和医疗保健相关感染。在1600 ppm的浓度下进行了一项时间依赖性功效研究。我们的研究旨在确定新开发的溶液是否保持长期有效性,并可作为抗菌剂使用,特别是在重症监护病房。方法:采用不同于标准臭氧化程序的技术开发的纳米泡脂质体溶液的抗菌试验,使用CLSI M07 A9(有氧生长细菌稀释抗菌敏感性试验方法;批准标准)标准试验方法,以最低抑菌浓度(MIC)值测试溶液,并测定其时间依赖性。对于纳米泡脂质体溶液的稳定性测试,根据ASTM F 1980标准,在55°C下保存74天,为两年稳定性。结果:纳米气泡臭氧溶液对MRSA和大肠杆菌(ATCC 25922)的MIC为1.562 ppm,标准试验方法为CLSI M07 A9(好氧生长细菌稀释药敏试验方法;批准的标准)。铜绿假单胞菌、鲍曼假单胞菌、耐甲氧西林金黄色葡萄球菌(MRSA) (ATCC12493)和大肠杆菌(atcc25922)。在2分钟内没有观察到活性,但在10分钟内发现1600 ppm纳米泡脂质体是有效的。在有效性方面,根据ASTM F 1980标准,该解决方案在2年后仍然有效,与预期相反。结论:纳米气泡臭氧储存在透明质酸修饰的脂质体溶液中,由于其无毒作用,对耐药细菌有效,且稳定性至少为两年,因此被认为在抗感染中发挥重要作用。在接下来的过程中,通过临床研究来支持该产品是合适的。
Nanobubble Ozone Stored in Hyaluronic Acid-Decorated Liposome Solutions: Inactivating Antibiotic-Resistant Bacteria and Genotoxicity, Sub-Acute and Sub-Chronic Toxicity Tests.
Introduction: Nanobubble ozone stored in hyaluronic acid-decorated liposomes (patent application PCT/TR2022/050177) was used, and the Minimum Inhibitory Concentration (MIC) was found to be 1562 ppm. Pseudomonas aeruginosa (patient isolate), Acinetobacter baumannii (patient isolate), Methicillin-Resistant Staphylococcus aureus (MRSA) (ATCC12493), and Escherichia coli (ATCC25922) bacteria, which are hospital-acquired and healthcare-associated infections, were used. A time-dependent efficacy study was conducted at 1600 ppm. Our study aimed to determine whether the newly developed solution maintains long-term effectiveness and can be used as an antibacterial agent, especially in intensive care units.
Methods: Antibacterial tests of the nanobubble liposome solution, developed with a different technique than the standard ozonation procedures, were performed with the CLSI M07 A9 (Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard) standard test method, and the solution was tested at Minimal Inhibitory Concentration (MIC) value and time-dependent effects were determined. For the stability test of the nanobubble liposome solution, according to the ASTM F 1980 standard, it was kept at 55 °C for 74 days as two-year stability.
Results: The MIC of the nanobubble ozone solution was 1.562 ppm for MRSA and E. coli (ATCC 25922) standard test method using CLSI M07 A9 (Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard). P. aeruginosa, A. baumannii, Methicillin-Resistant Staphylococcus aureus (MRSA) (ATCC12493), and E. coli (ATCC 25922). No activity was observed at 2 min, but 1600 ppm nanobubble liposomes at 10 min were found to be effective. In terms of effectiveness, the solution would still be effective after 2 years according to the ASTM F 1980 standard, contrary to expectations.
Conclusion: It is thought that nanobubble ozone stored in hyaluronic acid-decorated liposome solutions will play an important role in the fight against infections because of its non-toxic effect, effectiveness against resistant bacteria, and stability for at least two years. In the following process, it would be appropriate to support the product through clinical studies.
期刊介绍:
About Journal
Editors
Peer Reviewers
Articles
Article Publishing Charges
Aims and Scope
Call For Papers
ISSN: 1178-6973
Editor-in-Chief: Professor Suresh Antony
An international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventative strategies to minimize the development and spread of resistance.